The research base is primarily animal studies and small human trials from the 1980s–2000s, largely from Russian and German research groups. A 1988 controlled trial by Schneider-Helmert found that DSIP administered intravenously improved subjective sleep quality in 12 of 16 patients with chronic insomnia, with notable improvement in sleep architecture (more deep sleep, fewer nighttime awakenings).
A 2000 study in European Journal of Pharmacology confirmed DSIP's anxiolytic effects in animal models and noted that unlike benzodiazepines, it did not impair daytime cognitive performance.
Honest caveat: Modern placebo-controlled RCTs in large human populations are lacking. The available evidence is promising but not definitive. DSIP should be considered a legitimate investigational compound for sleep — not a proven pharmaceutical equivalent.
Clinical protocols for DSIP typically involve subcutaneous injection 30–60 minutes before sleep at doses of 100–500 mcg. Cyclic protocols (5 days on, 2 days off) are commonly used to prevent tachyphylaxis. DSIP is water-soluble and should be reconstituted in bacteriostatic water and refrigerated.
() is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from Epithalamin, a natural polypeptide produced by the pineal gland. It was developed and extensively studied by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in Russia — resulting in over 40 peer-reviewed publications.
's sleep relevance stems primarily from its effects on melatonin production. The pineal gland is responsible for synthesizing and releasing melatonin in response to darkness — the signal that initiates the transition to sleep. As we age, pineal function declines: peak melatonin production drops by 50–75% between age 20 and 60, contributing to the well-documented deterioration of sleep quality with aging.
A 2003 human trial (Korkushko et al.) in elderly patients with disturbed sleep-wake cycles found that a 10-day course produced measurable improvement in sleep-wake rhythmicity that persisted for 3–6 months after treatment cessation — a durability unusual for any sleep intervention.
Common protocols: 5–10 mg subcutaneous injection daily for 10–20 days, 1–2 times per year. Some practitioners use intranasal routes at higher doses. appears most effective for age-related sleep decline and circadian rhythm disruption rather than acute insomnia.
Body Protection Compound-157 () is a 15-amino-acid peptide derived from a gastroprotective protein found in gastric juice. It has a substantial and growing research base in recovery support, gut healing, and neurological protection — but is not a primary sleep peptide in the traditional sense.
So why does it appear in sleep discussions? Because many of the conditions that impair sleep are conditions addresses.
is best thought of as a foundational recovery peptide that improves the biological substrate on which sleep depends — not a direct sedative or sleep inducer.
Typical protocol: 250–500 mcg subcutaneous injection once daily, preferably in the morning or early afternoon (to avoid potential alerting effects). is available in both injectable and oral forms; oral delivery is appropriate for gut-specific applications, while subcutaneous is preferred for systemic effects.
For individuals with complex, multi-factorial sleep dysfunction, some practitioners combine these peptides.
| Peptide | Primary Mechanism for Sleep | Best Timing | Typical Duration |
|---|---|---|---|
| DSIP | Delta wave induction, cortisol reduction | 30–60 min before bed | Cyclic (5 on/2 off) |
| Melatonin restoration, circadian normalization | Evening or bedtime | 10–20 day courses, 1–2x/year | |
| HPA calming, gut-brain axis repair, neuroinflammation | Morning/afternoon | 8–12 weeks continuous |
Stacking requires medical supervision. Combining multiple peptides without guidance risks unnecessary expense and difficulty identifying which intervention is driving results or causing side effects.
Peptides for sleep are not pharmaceutical hypnotics. They do not produce the rapid, forceful sedation of zolpidem or temazepam. What patients who respond typically report.
Responses are highly individual. The strongest responders tend to be: individuals with HPA dysregulation (high nighttime cortisol), older adults with measurably low melatonin, and those with underlying gut inflammation or systemic inflammatory burden.
Consider discussing sleep peptides with your provider if.
Peptides should complement — not replace — foundational sleep hygiene: consistent sleep/wake timing, dark and cool sleeping environment, no screens 60 minutes before bed, alcohol avoidance, and stress management. No peptide overcomes a fundamentally disrupted sleep environment.
The evidence base for sleep peptides is growing but not yet at pharmaceutical-grade strength. What is clear is that for patients who are motivated, work with knowledgeable providers, and approach this with realistic expectations, DSIP, represent a low-risk, potentially high-reward addition to a comprehensive sleep optimization strategy.
Understanding the risk profile of each peptide is essential before starting any protocol.
In the available human studies (primarily European clinical research from the 1980s–2000s), DSIP was generally well-tolerated with no serious adverse events reported at standard doses. The most commonly reported effects were transient drowsiness (expected, given the mechanism) and, in a small minority, vivid dreaming during initial use. No hepatotoxicity, renal impairment, or dependence patterns have been documented. Because it is not a controlled substance and doesn't act directly on GABA-A receptors as a full agonist, it lacks the addiction potential of benzodiazepines.
Contraindications: No formal contraindications established, but use during pregnancy and lactation is not recommended due to absence of safety data. Interactions with existing sleep medications should be discussed with a provider before combining.
has the most extensive published safety record of the three, with the Russian research group reporting no significant adverse events across multiple multi-year human studies involving elderly populations. The most notable finding from long-term studies (Anisimov et al., Biogerontology2006) was actually a reduction in age-related pathology rather than any signal of harm. The tetrapeptide is rapidly cleared and does not appear to accumulate.
Given its telomerase-activating properties, theoretical concern about cancer promotion has been raised — but available animal data does not support this concern, and Khavinson's long-term cohort data in elderly patients showed reduced cancer incidence. This question remains worth monitoring as larger studies accumulate.
has been studied in hundreds of animal trials and has a strong preclinical safety profile. Human data is more limited but consistent with the animal findings: no serious adverse events reported in observational and preliminary human studies. The most commonly reported subjective effects are improved gut comfort, reduced soreness, and better energy — all consistent with its proposed mechanisms.
At standard doses (250–500 mcg), appears to have minimal side effect potential. Higher doses or combinations with other tissue-repair peptides (like TB-500) should be managed under medical supervision.
One of the best investments anyone serious about sleep optimization can make is a wearable sleep tracker. Devices like the Oura RingWHOOPand Garmin Fenix series track deep sleep duration, REM percentage, heart rate variability (HRV), and nighttime heart rate — giving objective data that complements subjective sleep quality reports.
When starting a peptide protocol for sleep, baseline your metrics for 2 weeks before the first injection, then track changes at 2 weeks, 4 weeks, and 8 weeks. Meaningful improvement typically manifests as.
If objective metrics improve but subjective sleep quality lags, this is common — the brain's subjective experience of sleep often adapts more slowly than the physiological data changes. Give a protocol 8–12 weeks of consistent use before drawing conclusions.
Conversely, if wearable data shows no change after 6 weeks, this is informative: either the peptide protocol isn't addressing your specific sleep issue, or an underlying cause (sleep apnea, restless legs, pain, stimulant use) is overriding the intervention. A provider review of the data alongside a sleep study referral may be appropriate at that point.
Board-certified providers. All 50 states. Get your personalized treatment plan today.
Start Your Free Consultation →